ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI - Trial NCT06388031
Access comprehensive clinical trial information for NCT06388031 through Pure Global AI's free database. This Phase 2 trial is sponsored by Peking Union Medical College Hospital and is currently Not yet recruiting. The study focuses on Non-small Cell Lung Cancer. Target enrollment is 27 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Peking Union Medical College Hospital
Timeline & Enrollment
Phase 2
May 10, 2024
Dec 10, 2027
Primary Outcome
Progression Free Survival (PFS)
Summary
An exploratory phase II trial of immune checkpoint inhibitors (ICIs, anti-PD-1/anti-PD-L1) as
 second-line treatment with advanced non-small cell lung cancer (NSCLC) who had long-term
 response to first-line immunotherapy (with or without chemotherapy).
 
 This study aims to evaluate efficacy and safety of ICI rechallenge in long-term responders to
 prior ICI. Furthermore, it seeks to identify biomarkers capable of predicting the efficacy of
 immunotherapy and prognosis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06388031
Non-Device Trial